If the epidermal growth factor receptor (EGFR) mutation is detected in advanced NSCLC, EGFR-tyrosine kinase inhibitors (TKIs), such as gefitinib, have become standard practice as first-line palliative chemotherapy.[5]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.